Recurrent vasovagal syncope following successful cardioneuroablation

Vasovagal syncope (VVS) is a common phenomenon, with upwards of 30%–45% of the population having suffered 1 VVS episode by the age of 60.1,2 It is a pathology that has frustrated many patients and providers in its suboptimal treatment response rate, and that has enacted an outsized economic impact on western societies.3 VVS subtypes are classified in 3 broad categories: a pure cardioinhibitory type (with and without asystole); a pure vasodepressor type, in which hypotension occurs without a significant decrease in heart rate (HR); and a mixed vasodepressor and cardioinhibitory type.